The insect vector always bites twice

The reality of the threat from vector-borne diseases has been recognized and the problem is prompting research scientists to take a strong interest. Most of these infections, classified as emerging or re-emerging diseases, are linked to ecosystem changes, climatic variations or pressure from human activities. Malaria, sleeping sickness and so on lead to the death of millions of people in the world. African countries are particularly strongly hit. The expansion of Dengue fever and the recent epidemics of Chikungunya and West Nile disease illustrate the trend.

The pathogens responsible for these diseases can be viruses, bacteria or protozoans which are passed on to humans by an arthropod vector, most often a dipteran insect. This becomes infected when it feeds, taking blood from an infected vertebrate host. The pathogenic agent finds conditions to reproduce and proliferate in the vector’s body. In most cases, the parasite moves back into the vector’s salivary glands in order to be transmitted to the human host when the insect bites again to take another blood meal. Morbidity among infected people is therefore associated with the degree of exposure of the subject to insect vector bites.

The vector saliva, which is adapted for blood feeds, plays a prime role in the transmission of the associated diseases. It contains numerous proteins, including immunogenic ones that can modulate or induce a human immune response. Working for the EpiVect programme initiated in 2003, scientists from IRD research unit UR 024 studied this still little known response with the aim of identifying in the arthropod vector saliva the immunogenic proteins responsible. They called on immunological techniques to evaluate qualitatively and quantitatively, in the serum sampled from human populations living in transmission areas, the presence of antibodies targeting specifically these proteins contained in an extract of total saliva of the culprit vector.

This approach, based on the studies of malaria transmission by mosquitoes of the genus Anopheles and human African trypanosomiasis (sleeping sickness) by Glossinia species or tsetse flies, revealed that the antibody response can represent a good indicator of the degree of exposure of humans to bites, which could in the long term allow improved assessment of the risk of transmission of these diseases in a given region.

In Senegal the rate of antisalivary antibodies against Anopheles in young children (under 5 years), the population most exposed to the risk of malaria, appeared to be proportional to the actual degree of exposure, which had been assessed beforehand by standard entomological capture techniques. All the children involved in the study showed a higher level during the period of most intense transmission, in September. The antibody rate proved also to be associated with the risk of occurrence of a malarial attack in the following three months. These antisalivary antibodies consequently seem to be indicators of the risk of malaria in endemic areas, that could be used to improve strategies of prevention and care of young patients in the context of seasonal transmission of the disease.

The objective of the work conducted on human African trypanosomiasis was to analyse the antibody response to identify exactly, in total saliva extract of Glossinia flies, the immunogenic proteins responsible for synthesis of these specific antibodies. The different saliva proteins of four Glossinia species, uninfected, vectors or non-vectors, were separated then put into contact with the serum of individual subjects, infected or uninfected, exposed to bites. Comparison of salivary protein immunogenic profiles obtained showed that they differ depending on the infection status of the subjects (exposed uninfected/infected) and the vector or non-vector status of the Glossinia. Hence, immunogenic proteins specific for two Glossinia species investigated (a 42 kDa protein in G. fuscipes fuscipes, and 50, 55, 65 and 72 kDa proteins in G. morsitans morsitans) could be used to assess specifically the degree of exposure to bites of each of these species.

Starting from immunogenic salivary proteins, simple and effective prevention tools (immuno-tests) can be devised to assess the exposure of human subjects, or be used in endemic areas to evaluate the efficacy of existing vector control strategies, such as the use of impregnated mosquito nets. Analysis of the host-vector relationship, up to now dealt with mainly from the angle of allergic responses to bites or in the search for veterinary vaccines, constitutes now an important research path for new surveillance and prevention strategies.

Source: Institut de Recherche Pour le Développement

Related stories:

Study finds unique HIV vaccine formula elicits strong immune responses
Today, Advanced BioScience Laboratories, Inc. and the University of Massachusetts Medical School report that their unique HIV vaccine formulation was effective in eliciting strong and balanced immune responses in healthy human volunteers.
Researchers develop improved gene therapy agent
Replacing one amino acid on the surface of a virus that shepherds corrective genes into cells could be the breakthrough scientists have needed to make gene therapy a more viable option for treating genetic diseases such as hemophilia, University of Florida researchers say.
New vaccine may give long-term defense against deadly bird flu and its variant forms
A new vaccine under development may provide protection against highly pathogenic bird flu and its evolving forms, according to researchers at Purdue University and the Centers for Disease Control and Prevention who discovered the new preventative drug and have tested it in mice.
Pharmaceutical breakthrough may make a range of drugs cheaper and more available
A new study published in the February 2008 print edition of The FASEB Journal describes a scientific advance that should reduce the cost and increase the availability of a wide range of drugs. In the report, University of Pennsylvania researchers describe how they used gene therapy to reduce the time it takes to breed large animals capable of producing therapeutic proteins in their milk, such as insulin or those that fight cancer. This represents a significant milestone in drug development, as current methods involve cloning, which takes more time and generally costs more.
Freeze-dried tendon implants prove effective in early studies
Donated, freeze-dried tendon grafts loaded with gene therapy may soon offer effective repair of injured tendons, a goal that has eluded surgeons to date. According to study data published today in the journal Molecular Therapy, a new graft technique may provide the first effective framework around which flexor tendon tissue can reorganize as it heals.
New strategies work to put cancer on the firing line
Dr. Yukai He wants to put cancer in the bull’s eye.“Cancer really comes from us,” the Medical College of Georgia Cancer Center immunologist says of the scary reality that cancer cells are our own cells gone awry. That means our immune system doesn’t always see cancer as a horrific invader.
New chimeric mouse model for human liver diseases, drug testing
Cells cultured in the lab are like a fish out of water. Often, their behavior does not reflect their biological function within an entire organ or organism, which, for example, turns studying human liver cells into a big challenge.
T vs. B: Re-engineered human T cells effectively target and kill cancerous B cells
Human white blood cells, engineered to recognize other malignant immune cells, could provide a novel therapy for patients with highly lethal B cell cancers such as acute lymphoblastic leukemia (ALL), according to researchers at Memorial Sloan-Kettering Cancer Center (MSKCC). By administering repeated doses of T cells designed to express an artificial receptor which recognizes human B cells, the researchers were able to eradicate cancer in 44 percent of mice bearing human ALL tumors.

News discussion:

Medicine & Health news